My Cart

EGFRvIII

EGFRvIII Overview

English NameEpidermal growth factor receptor variant IIIApproved Drugs0
Drugs in Clinical Trials13Target Synonym
Highest Development StagePhase 2 Clinical
English NameEpidermal growth factor receptor variant III
Target Synonym
Approved Drugs0
Drugs in Clinical Trials13
Highest Development StagePhase 2 Clinical

EGFRvIII Background

The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands. The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Mutations affecting EGFR expression or activity could result in cancer. The type III EGF deletion mutant receptor (EGFRvIII) is the most common mutation and was first identified in primary human glioblastoma tumors. This tumor-specific antigen is ligand-independent, contains a constitutively active tyrosine kinase domain, and has been shown to be present in a number of human malignancies. EGFRvIII has been selected as a target for CAR-modified T-cell studies in recent years.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
WSD-0922WSD0922; WSD-0922Phase 2 ClinicalWayshine Biopharm International LtdGlioblastoma; Neoplasms; Astrocytoma; Carcinoma, Non-Small-Cell Lung
Details
Anti-EGFRvIII-CAREGFRvIII CAR; Anti-EGFRvIII-CARPhase 2 ClinicalNational Cancer Institute, Kite PharmaGlioblastoma; Brain Neoplasms; Gliosarcoma; Glioma
Details
Recombinant anti-EGFR chimeric monoclonal antibody (Shanghai CP Guojian)CPGJ-602; 602; CPGJ602; CPGJ 602Phase 2 ClinicalSunshine GuoJian Pharmaceutical (Shanghai) Co LtdColorectal Neoplasms
Details
WSD-0922-FUWSD0922-FU; WSD-0922-FUPhase 2 ClinicalWayshine Biopharm International LtdCarcinoma, Non-Small-Cell Lung
Details
EGFRvIII-directed CAR-T cell tharapy (Novartis/University of Pennsylvania)LXF-821Phase 1 ClinicalUniversity Of Pennsylvania, Novartis Pharma AgGlioblastoma
Details
EGFRvIII-CARPhase 1 ClinicalDuke University Medical CenterGlioblastoma
Details
APTN-101APTN 101Phase 1 ClinicalAdaptin BioGlioblastoma
Details
Autologous Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13R alpha2 CAR (E-SYNC) T Cells therapy(California Institute For Regenerative Medicine)Phase 1 ClinicalCalifornia Institute For Regenerative Medicine, National Cancer InstituteGlioblastoma
Details
CBRX-101CBRX-101Phase 1 ClinicalCentaur Bio IncGlioblastoma; Glioma
Details
Targeted EGFRvIII autochimeric antigen receptor T cell therapy (DCTY)DCTY0801; DCTY-0801Phase 1 ClinicalBeijing DCTY Biotech Co LtdGlioblastoma
Details
SNC-109SNC109; SNC-109Phase 1 ClinicalShanghai Simnova Biotechnology Co LtdGlioblastoma
Details
RO-7428731RO-7428731; RG-6156Phase 1 ClinicalF. Hoffmann-La Roche LtdGlioblastoma
Details
GNC-039GNC-039Phase 1 ClinicalSichuan Baili Pharmaceutical Co LtdSolid tumours; Hematologic Neoplasms; Glioma; Neoplasm Metastasis
Details
  • Overview
  • Product List
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland